NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-21-164 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-22-006 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to expand the use of existing ADRD data resources to drive, via computational model development and dissemination, new discoveries that can lead to better understanding of mechanisms, clinical risk assessment and outcomes, and to identify novel candidate biomarkers for ADRD.
Notice NOT-OD-21-166 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-293 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for the Clinical and Translational Science Award (CTSA) Program hubs that will be part of a national, collaborative consortium focused on bringing more treatments to more patients more quickly through advancing clinical and translational science (CTS) by (1) developing, demonstrating, and disseminating scientific and operational innovations that improve the efficiency and effectiveness of clinical translation from identification to first-in-human studies to medical practice implementation to community health dissemination; (2) promoting partnerships and collaborations to facilitate and accelerate translational research projects locally, regionally, and nationally; (3) creating, providing, and disseminating innovative research programs and partnerships across institutions and communities to address health disparities and deliver the benefits of translational science to all; (4) creating and implementing scientific and operational innovations that increase the quality, safety, efficiency, effectiveness, and informativeness of clinical research; (5) providing a national resource for the rapid response to urgent public health needs; and (6) creating, providing, and disseminating CTS training for clinical research professionals of all disciplines on the research team. Along with this solicitation for the UM1 CTSA hub application, NCATS has published a separate, companion FOA that solicits applications for a required K12 Clinical Scientist Institutional Career Development Program Award (PAR-TR-22-career); both a UM1 hub application and the required K12 application must be submitted. If there is no companion K12 application submitted, the UM1 hub application will not be reviewed. However, if the UM1 application is funded and the companion K12 application is not funded, a resubmitted K12 application will be accepted. Additional companion FOAs solicit applications for optional training, career, and research ed
Notice NOT-ES-21-009 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-255 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address increasingly larger data sets.
Funding Opportunity PAR-21-254 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address increasingly larger data sets.
Notice NOT-HG-21-039 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-002 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-256 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NINDS R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.
Notice NOT-DA-21-066 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-171 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-011 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-22-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to continue research projects with robustly validated targets for Substance Use Disorders (SUDs). This FOA will provide funding for projects entering at either assay development (AD), lead identification (LI), lead optimization (LO), or preclinical development (PCD) stages to allow for the ultimate goal of successfully completing Investigational New Drug-enabling activities.
Funding Opportunity RFA-DA-22-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) to continue research projects with robustly validated targets for Substance Use Disorders (SUDs). This FOA will provide funding for projects entering at either assay development (AD), lead identification (LI), lead optimization (LO), or preclinical development (PCD) stages to allow for the ultimate goal of successfully completing Investigational New Drug-enabling activities.
Notice NOT-ES-21-011 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-059 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-071 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-049 from the NIH Guide for Grants and Contracts. The mission of the National Cancer Institute (NCI) Division of Cancer Biology (DCB) is to ensure continuity and stability in basic cancer research while encouraging and facilitating the emergence of new concepts, technologies, and possibilities. Towards its mission, the DCB supports multiple collaborative research programs focused on addressing important questions in basic cancer biology. To maximize the combined impact of DCB programs, this FOA aims to support a common coordinating body to facilitate collaborations, resource sharing, and outreach activities across DCB programs. DCB research programs to be coordinated by the DCB Multi-Consortia Coordinating Center (MC2 Center) include the Cancer Cell Biology Imaging Resource (CCBIR), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Metastasis Research Network (MetNet), the Patient-Derived Models of Cancer Initiative (PDMC), and the Physical Sciences-Oncology Network (PS-ON). In carrying out its roles, the MC2 Center is expected to work collaboratively with DCB research program investigators, other investigators collaborating with DCB research programs, and NCI program staff.
Funding Opportunity RFA-DK-21-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support pilot and feasibility trials of interventions designed to improve technology adoption in individuals from underrepresented backgrounds with type 1 diabetes mellitus (T1D). Through successful execution, these pilot and feasibility trials should provide feasibility data for larger, pragmatic trials with the overarching goal of reducing health disparity in T1D through improving technology usage in individuals from minority racial and ethnic backgrounds.